Harrow, Inc. (HROW)
35.21
-0.18
(-0.51%)
USD |
NASDAQ |
May 29, 16:00
35.50
+0.29
(+0.82%)
After-Hours: 20:00
Harrow EPS Diluted (Quarterly) : -0.7414 for March 31, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Eli Lilly & Co. | 8.255 |
| Liquidia Corp. | 0.5228 |
| Corcept Therapeutics, Inc. | -0.2988 |
| Esperion Therapeutics, Inc. | -0.1002 |
| Theravance Biopharma, Inc. | -0.0962 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -27.60M |
| Revenue (Quarterly) | 44.20M |
| Total Expenses (Quarterly) | 71.80M |
| Enterprise Value | 1.518B |
| Gross Profit Margin (Quarterly) | 61.18% |
| Profit Margin (Quarterly) | -62.44% |
| Earnings Yield | -1.16% |
| Operating Earnings Yield | 2.10% |
| Normalized Earnings Yield | -0.313 |